GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Philogen SpA (STU:78Q) » Definitions » FCF Margin %

Philogen SpA (STU:78Q) FCF Margin % : 68.25% (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Philogen SpA FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Philogen SpA's Free Cash Flow for the six months ended in Dec. 2024 was €49.97 Mil. Philogen SpA's Revenue for the six months ended in Dec. 2024 was €73.22 Mil. Therefore, Philogen SpA's FCF Margin % for the quarter that ended in Dec. 2024 was 68.25%.

As of today, Philogen SpA's current FCF Yield % is 4.61%.

The historical rank and industry rank for Philogen SpA's FCF Margin % or its related term are showing as below:

STU:78Q' s FCF Margin % Range Over the Past 10 Years
Min: -1035.66   Med: -46.21   Max: 51.94
Current: 51.94


During the past 5 years, the highest FCF Margin % of Philogen SpA was 51.94%. The lowest was -1035.66%. And the median was -46.21%.

STU:78Q's FCF Margin % is ranked better than
96.71% of 1004 companies
in the Biotechnology industry
Industry Median: -126.31 vs STU:78Q: 51.94


Philogen SpA FCF Margin % Historical Data

The historical data trend for Philogen SpA's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Philogen SpA FCF Margin % Chart

Philogen SpA Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
FCF Margin %
-351.90 -1,035.66 -38.59 -46.21 51.94

Philogen SpA Semi-Annual Data
Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only -206.68 39.89 -1,283.39 -1,481.00 68.25

Competitive Comparison of Philogen SpA's FCF Margin %

For the Biotechnology subindustry, Philogen SpA's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Philogen SpA's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Philogen SpA's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Philogen SpA's FCF Margin % falls into.


;
;

Philogen SpA FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Philogen SpA's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=38.43/73.996
=51.94 %

Philogen SpA's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin=Free Cash Flow (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=49.967/73.217
=68.25 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Philogen SpA FCF Margin % Related Terms

Thank you for viewing the detailed overview of Philogen SpA's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Philogen SpA Business Description

Traded in Other Exchanges
Address
Piazza La Lizza No. 7, Siena, ITA, 53100
Philogen SpA is a biotechnology company. The company develops biotech products for the imaging and therapy of life-threatening diseases. The company's focus is predominantly related to oncology drug development, although the company has also brought products for the treatment of chronic inflammatory diseases to the clinic. Its pipeline products include Nidlegy; Fibromun; Darleukin; Dodekin; Dekavil and others. Geographically, the company operates in the European Union, Switzerland, and the United States of America.

Philogen SpA Headlines

No Headlines